Vir Biotechnology Inc (VIR) fair value: what the stock is really worth
As of Nov 16, 2026: fair value (intrinsic value) of Vir Biotechnology Inc stock $8.04, price $9.58, that is 16.1% below the price, quality 38 out of 100. Rating: overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.
- Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free
Vir Biotechnology Inc
VIR · USExpensive (fair value 16% below the price) and weak company, but rising price: meets 1 of 3 rules.
What runs behind every stock
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 17, 2026.
How to read this chart
60‑month range $4.28 – $54.54 · fair‑value band $6.03 – $10.05 · the $9.58 price screens above the $8.04 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 17, 2026.
Every Wednesday you see whether Vir Biotechnology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Company profile
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally.
Show moreShow less
Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors.
The company's preclinical candidates include those targeting influenza A and B antibodies and antibody drug conjugates, and coronavirus monoclonal antibodies; and PRO-XTEN, a dual-masked TCEs targeting variety of solid tumors.
It has grant collaboration and license agreement with Astellas; license agreement with Norgine for the treatment of CHD; amended and restated letter agreement with the Gates Foundation; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreement with the Institute for Research in Biomedicine; a license agreement with The Rockefeller University; license agreements with Xencor; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.
Stock analysis
Vir Biotechnology Inc (VIR) currently trades at $9.58, while our estimate is $8.04, 16% below the price, so the stock looks overvalued today.
Show more
Valuation
None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.
Scenario range: $6.03 (bear) to $10.05 (bull), the price of $9.58 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 38/100 (below-average quality), in the Healthcare sector.
Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.
Vir Biotechnology Inc reported revenue of $68.6M in FY2025 versus $1.1B in FY2021, a compound −50.0%/yr. Reported net income was −$438M in FY2025.
Key figures
Market cap $2.1B Mid · P/S ratio 6.91 · EPS (TTM) $−1.18 · Net margin −61.0% · Return on equity −21.8% · Return on assets (EBIT) −14.6% (5-year average) · Operating margin 55,669% · Revenue growth (YoY) +196%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 8 out of 100 (low confidence).
What moves the price
The share trades about 30% below its 52-week high and 76% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −16%, VIR screens richer than that median.
Fair Value
Quality Score breakdown
It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.
Insider trades
In the last 6 months, 3 officers or directors sold shares worth $75,761 and none bought.
- SaleVanina de VerneuilEVP, General Counsel, Corp Sec3× since Feb 23, 2026: 25,012 shares, avg. $9.57$239,294Nov 3, 202610b5-1 plan
- SaleBrent SabatiniSVP, Chief Accounting Officer5× since Feb 13, 2026: 12,879 shares, avg. $8.78$113,079Jun 1, 202610b5-1 plan
- SaleJanet NapolitanoDirector3,200 shares at $9.45$30,240Jun 1, 202610b5-1 plan
- SaleVicki L SatoDirector7× since Dec 1, 2025: 174,377 shares, avg. $8.46$1.5MMay 1, 202610b5-1 plan
- SaleMarianne De BackerPresident and CEO, Director3× since Feb 23, 2026: 106,360 shares, avg. $8.91$947,163Apr 6, 202610b5-1 plan
- SaleMark EisnerEVP and Chief Medical Officer2× since Feb 23, 2026: 5,594 shares, avg. $8.85$49,514Feb 25, 202610b5-1 plan
- SaleJason O'ByrneEVP & Chief Financial Officer3× since Nov 17, 2025: 10,522 shares, avg. $6.55$68,938Feb 24, 202610b5-1 plan
- SaleSVF Endurance (Cayman) Ltd10% owner2× since Nov 24, 2025: 655,628 shares, avg. $6.18$4.1MDec 1, 202510b5-1 plan
- SaleSOFTBANK VISION FUND (AIV M1) L.P.10% owner189,431 shares at $6.41$1.2MNov 28, 202510b5-1 plan
Plus 11 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.
Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.
Source: SEC Form 4, as of Nov 16, 2026. All filings at the SEC ↗
Revenue & earnings trend
Recent news
- Biggest stock movers Monday: NVDA, VIR, and more
- Vir Biotechnology reports positive hepatitis results, early signs of possible cure
- Vir Biotechnology Announces Expanded Phase 2 SOLSTICE Data for Elebsiran and Tobevibart in Chronic Hepatitis Delta, Showing Deep and Sustain
- Vir Biotechnology Inc (VIR) (Q3 2026) Earnings Call Highlights: Hepatitis Delta Data on Deck ...
Compare Vir Biotechnology Inc with another stock
Price, fair value, quality and upside side by side.
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 850 stocks
Valuation Multiplesvs Biotechnology median · lower = cheaper
Strength profile in five axes (Snowflake)
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- P/S ratio by industry
- EBIT margin by industry
- PEG screener for stocks with fair value
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value | Compare |
|---|---|---|---|---|
| Regeneron Pharmaceuticals, Inc REGN | $952.40 | $1,275 | +34% | vs VIR |
| Vertex Pharmaceuticals Incorporated VRTX | $537.79 | $592.46 | +10% | vs VIR |
| Samsung Biologics Co 207940 | 1,414,000 KRW | 1,552,100 KRW | +10% | vs VIR |
| argenx SE ARGX | $950.95 | $908.40 | −4% | vs VIR |
| CSL Limited CSL | A$199.55 | A$186.49 | −7% | vs VIR |
| Moderna, Inc MRNA | $215.27 | $135.64 | −37% | vs VIR |
| BeOne Medicines AG 6160 | HK$247.40 | HK$152.92 | −38% | vs VIR |
| Revolution Medicines, Inc RVMD | $166.87 | $88.78 | −47% | vs VIR |
| Celltrion, Inc 068270 | 213,000 KRW | 74,945 KRW | −65% | vs VIR |
| Royalty Pharma plc RPRX | $68.53 | $19.01 | −72% | vs VIR |
Explore undervalued stocks
More undervalued Healthcare stocks →
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Vir Biotechnology Inc (VIR) overvalued or undervalued?
What is the fair value of VIR?
What is the quality score of VIR?
What is the price target for Vir Biotechnology Inc (VIR)?
What is the Vir Biotechnology Inc stock forecast for 2026?
What is the intrinsic value of Vir Biotechnology Inc (VIR)?
Is Vir Biotechnology Inc stock overvalued or undervalued in 2026?
Is fair value the same as the market price of VIR?
How much is Vir Biotechnology Inc worth?
What do the bullish and bearish scenarios say about VIR?
How solid is the balance sheet of Vir Biotechnology Inc (VIR)?
How far is VIR from its 52-week high?
Which stocks are comparable to Vir Biotechnology Inc?
Is Vir Biotechnology Inc stock attractive at the current price?
Is it still worth investing in stocks now?
What is the share price of Vir Biotechnology Inc (VIR)?
What should I pay attention to with Vir Biotechnology Inc right now?
Key figures of Vir Biotechnology Inc
How large is the market capitalisation of Vir Biotechnology Inc (VIR)?
What is the P/S ratio of Vir Biotechnology Inc (VIR)?
What are the earnings per share of Vir Biotechnology Inc (VIR)?
What is the net margin of Vir Biotechnology Inc (VIR)?
What is the return on equity of Vir Biotechnology Inc (VIR)?
What is the EBIT return on assets of Vir Biotechnology Inc (VIR)?
What is the operating margin of Vir Biotechnology Inc (VIR)?
How fast is revenue growing at Vir Biotechnology Inc (VIR)?
How fast are earnings growing at Vir Biotechnology Inc (VIR)?
How much free cash flow does Vir Biotechnology Inc (VIR) generate?
How much net cash does Vir Biotechnology Inc (VIR) hold?
Watch Vir Biotechnology Inc in the live analysis
One click puts Vir Biotechnology Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.